What are Alphamers®
Alphamer® molecules have been designed to be modular, comprising three components which provide a unique combination of targeting, stable linking, and immunological properties. Utilizing a proprietary antibody recruiting molecule (ARM) to harness the power of the natural antibody repertoire, Alphamers have the potential to be effective in even the most vulnerable and immune-compromised patients.
The customizable structure of the targeting moiety recognizes and binds to a target of interest, which may be a small molecule, monoclonal antibody or peptide. The proprietary stable linker joins the targeting moiety to an immunological effector moiety, which displays sugar epitopes, leading to the recruitment of the host’s pre-existing polyclonal antibody repertoire.
Our current extensive patent of the Alphamer platform is covering infectious diseases and oncology.
Kary Mullis PhDScience consistently produces a new crop of miraculous truths and dazzling devices every year.
Nobel Laureate and inventor of Alphamer concept (1944-2019)